GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

TPG Biotech to Fund Development of Two Drugs from JCR

  • TPG Biotech will fund the late-stage clinical development of two drug candidates from JCR Pharmaceuticals: JR-013 and Growject®. Under the terms of the agreement, TPG Biotech will fund the development of the drugs and in return will receive milestone payments, royalties, and warrants to purchase JCR’s common stock.

    JR-013 is a recombinant human erythropoietin for the treatment of renal anemia in dialysis patients. The drug was originated by JCR and is currently undergoing Phase II/III studies in Japan.

    Growject is currently approved and marketed in Japan to treat short stature in children with growth hormone deficiency and Turner’s syndrome. JCR is extending Growject use to treat adult growth hormone deficiency (AGHD). Clinical studies for AGHD have been completed and application for an approval of this extended use has been filed with the Japanese Ministry of Health, Labor and Welfare.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »